Memphasys Ltd (AU:MEM) has released an update.
Memphasys Ltd, a pioneering Australian biotechnology firm, is inviting shareholders to a webinar to share updates on its Felix System clinical trials, which are nearing completion. The company is eyeing a quicker entry into the European market with a fast-tracked regulatory strategy. Additionally, Memphasys has embarked on a 3-year equine study expected to yield commercial results within a year.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
